BiotechTube
Home/Sandoz Group/Rebecca Guntern
RG

Rebecca Guntern

Head of Strategy & Innovation

Sandoz Group

Therapeutic Areas

OncologyImmunologyAnti-infectivesCardiovascularCentral Nervous System

Sandoz Group Pipeline

DrugIndicationPhase
Hyrimoz (adalimumab)Chronic Inflammatory DiseasesMarketed
Ziextenzo (pegfilgrastim)Chemotherapy-induced NeutropeniaMarketed
Erelzi (etanercept)Rheumatoid Arthritis, Plaque PsoriasisMarketed
Ustekinumab BiosimilarPlaque Psoriasis, Crohn's DiseasePhase III
Denosumab BiosimilarOsteoporosis, Cancer-related Bone LossPhase III
Bevacizumab BiosimilarVarious CancersPhase III

Leadership Team at Sandoz Group

RS
Richard Saynor
Chief Executive Officer
GG
Gilbert Ghostine
Chairman of the Board
RB
Remy B.
Chief Financial Officer
KH
Keren Haruvi
President, Sandoz North America
PB
Pierre Bourdage
President, Sandoz International
View full Sandoz Group profile